Cardiogenic Shock Guidance; Mortality after Mitral Repair & TAVR; Direct-to-Physician Marketing Affects GDMT
In this week’s View, Dr. Eagle looks at the latest clinical guidance on the management of cardiogenic shock. He then discusses trends in mortality after mitral repair and TAVR. Finally, Dr. Eagle offers a brief exploration into how direct-to-physician industry marketing affects rates of guideline-directed medical therapy (GDMT) surrounding heart failure patients.
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Cardiac Surgery, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Valvular Heart Disease, Cardiac Surgery and Heart Failure, Cardiac Surgery and VHD, Acute Heart Failure, Heart Failure and Cardiac Biomarkers, Interventions and Structural Heart Disease, Mitral Regurgitation
Keywords: Shock, Cardiogenic, Myocardial Infarction, Hemodynamics, Cardiovascular Critical Care, Heart Failure, Critical Care, National Cardiovascular Data Registries, STS/ACC TVT Registry, Transcatheter Aortic Valve Replacement, Mitral Valve Insufficiency, Cause of Death, CCR5 Receptor Antagonists, Mineralocorticoid Receptor Antagonists, Neprilysin, Centers for Medicare and Medicaid Services, U.S., Sodium-Glucose Transporter 2 Inhibitors, Angiotensin-Converting Enzyme Inhibitors, Medicare Part D
